A number of recent papers have focused attention on the remarkable responses seen with glutamatergic agents in major depressive disorder (MDD), raising questions about the  monoamine hypothesis of psychiatric disorders that has dominated biological psychiatry for a half century (Schildkraut JJ. Am J Psychiatry 1965;122:509-522).